Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014, Article ID 568693, 13 pages
http://dx.doi.org/10.1155/2014/568693
Research Article

Biological and Molecular Effects of Small Molecule Kinase Inhibitors on Low-Passage Human Colorectal Cancer Cell Lines

1Department of Medicine II, Division of Gastroenterology, Rostock University Medical Center, Ernst-Heydemann-Straße 6, 18057 Rostock, Germany
2Oscar Langendorff Institute of Physiology, Rostock University Medical Center, Gertrudenstraße 9, 18057 Rostock, Germany
3Molecular Oncology and Immunotherapy, Department of General Surgery, Rostock University Medical Center, Schillingallee 35, 18057 Rostock, Germany
4Institute of Pathology, Rostock University Medical Center, Strempelstraße 14, 18055 Rostock, Germany

Received 27 June 2014; Accepted 26 August 2014; Published 17 September 2014

Academic Editor: Raj Kumar

Copyright © 2014 Falko Lange et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. Siegel, J. Ma, Z. Zou, and A. Jemal, “Cancer statistics, 2014,” CA: Cancer Journal for Clinicians, vol. 64, no. 1, pp. 9–29, 2014. View at Publisher · View at Google Scholar · View at Scopus
  2. Y.-D. Cheng, H. Yang, G.-Q. Chen, and Z.-C. Zhang, “Molecularly targeted drugs for metastatic colorectal cancer,” Drug Design, Development and Therapy, vol. 7, pp. 1315–1322, 2013. View at Publisher · View at Google Scholar · View at Scopus
  3. S. M. Wilhelm, J. Dumas, L. Adnane et al., “Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity,” International Journal of Cancer, vol. 129, no. 1, pp. 245–255, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. A. Grothey, E. Van Cutsem, A. Sobrero et al., “Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial,” The Lancet, vol. 381, no. 9863, pp. 303–312, 2013. View at Publisher · View at Google Scholar · View at Scopus
  5. T. Efferth, “Signal transduction pathways of the epidermal growth factor receptor in colorectal cancer and their inhibition by small molecules,” Current Medicinal Chemistry, vol. 19, no. 33, pp. 5735–5744, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. E. Martinelli, T. Troiani, E. D'Aiuto et al., “Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells,” International Journal of Cancer, vol. 133, no. 9, pp. 2089–2101, 2013. View at Publisher · View at Google Scholar · View at Scopus
  7. S. Yoon and R. Seger, “The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions,” Growth Factors, vol. 24, no. 1, pp. 21–45, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. C. Montagut and J. Settleman, “Targeting the RAF-MEK-ERK pathway in cancer therapy,” Cancer Letters, vol. 283, no. 2, pp. 125–134, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. S. Ogino, J. A. Meyerhardt, N. Irahara et al., “KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803,” Clinical Cancer Research, vol. 15, no. 23, pp. 7322–7329, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. M. Brink, A. F. P. M. de Goeij, M. P. Weijenberg et al., “K-ras oncogene mutations in sporadic colorectal cancer in The Netherlands Cohort Study,” Carcinogenesis, vol. 24, no. 4, pp. 703–710, 2003. View at Publisher · View at Google Scholar · View at Scopus
  11. H. Davies, G. R. Bignell, C. Cox et al., “Mutations of the BRAF gene in human cancer,” Nature, vol. 417, no. 6892, pp. 949–954, 2002. View at Publisher · View at Google Scholar · View at Scopus
  12. P. M. Wilson, M. J. LaBonte, and H.-J. Lenz, “Molecular markers in the treatment of metastatic colorectal cancer,” The Cancer Journal, vol. 16, no. 3, pp. 262–272, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. K.-K. Wong, J. A. Engelman, and L. C. Cantley, “Targeting the PI3K signaling pathway in cancer,” Current Opinion in Genetics & Development, vol. 20, no. 1, pp. 87–90, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. S. Ward, Y. Sotsios, J. Dowden, I. Bruce, and P. Finan, “Therapeutic potential of phosphoinositide 3-kinase inhibitors,” Chemistry & Biology, vol. 10, no. 3, pp. 207–213, 2003. View at Publisher · View at Google Scholar · View at Scopus
  15. N. T. Ihle, G. Powis, and S. Kopetz, “PI-3-Kinase inhibitors in colorectal cancer,” Current Cancer Drug Targets, vol. 11, no. 2, pp. 190–198, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. T. L. Yuan and L. C. Cantley, “PI3K pathway alterations in cancer: variations on a theme,” Oncogene, vol. 27, no. 41, pp. 5497–5510, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. J. Tsai, J. T. Lee, W. Wang et al., “Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 8, pp. 3041–3046, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. A. G. Gilmartin, M. R. Bleam, A. Groy et al., “GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition,” Clinical Cancer Research, vol. 17, no. 5, pp. 989–1000, 2011. View at Publisher · View at Google Scholar · View at Scopus
  19. S. B. Kondapaka, S. S. Singh, G. P. Dasmahapatra, E. A. Sausville, and K. K. Roy, “Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation,” Molecular Cancer Therapeutics, vol. 2, no. 11, pp. 1093–1103, 2003. View at Google Scholar · View at Scopus
  20. K. T. Flaherty, I. Puzanov, K. B. Kim et al., “Inhibition of mutated, activated BRAF in metastatic melanoma,” The New England Journal of Medicine, vol. 363, no. 9, pp. 809–819, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. S. Kopetz, J. Desai, E. Chan et al., “PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors,” Journal of Clinical Oncology, vol. 28, supplement, abstract 3534, no. 15, 2010. View at Google Scholar
  22. R. B. Corcoran, H. Ebi, A. B. Turke et al., “EGFR-mediated reactivation of MAPK signaling contributes to insensitivity of BRAF-mutant colorectal cancers to RAF inhibition with vemurafenib,” Cancer Discovery, vol. 2, no. 3, pp. 227–235, 2012. View at Publisher · View at Google Scholar · View at Scopus
  23. M. Mao, F. Tian, J. M. Mariadason et al., “Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents,” Clinical Cancer Research, vol. 19, no. 3, pp. 657–667, 2013. View at Publisher · View at Google Scholar · View at Scopus
  24. T. Yamaguchi, R. Kakefuda, N. Tajima, Y. Sowa, and T. Sakai, “Antitumor activities of JTP-74057 (GSK1120212), a novel MEK1/2 inhibitor, on colorectal cancer cell lines in vitro and in vivo,” International Journal of Oncology, vol. 39, no. 1, pp. 23–31, 2011. View at Publisher · View at Google Scholar · View at Scopus
  25. M. Watanabe, Y. Sowa, M. Yogosawa, and T. Sakai, “Novel MEK inhibitor trametinib and other retinoblastoma gene (RB)-reactivating agents enhance efficacy of 5-fluorouracil on human colon cancer cells,” Cancer Science, vol. 104, no. 6, pp. 687–693, 2013. View at Publisher · View at Google Scholar · View at Scopus
  26. J. C. Bendell, J. Nemunaitis, S. J. Vukelja et al., “Randomized placebo-controlled phase II trial of perifosine, plus capecitabine as second- or third-line therapy in patients with metastatic colorectal cancer,” Journal of Clinical Oncology, vol. 29, no. 33, pp. 4394–4400, 2011. View at Publisher · View at Google Scholar · View at Scopus
  27. J. C. Bendell, T. Ervin, N. Senzer et al., “Results of the X-PECT study: a phase III randomized double-blind, placebo-controlled study of perifosine plus capecitabine (P-CAP) versus placebo plus capecitabine (CAP) in patients (pts) with refractory metastatic colorectal cancer (mCRC),” Journal of Clinical Oncology, vol. 30, 2012. View at Google Scholar
  28. M. B. Chen, X. Y. Wu, G. Q. Tao et al., “Perifosine sensitizes curcumin-induced anti-colorectal cancer effects by targeting multiple signaling pathways both in vivo and in vitro,” International Journal of Cancer, vol. 131, no. 11, pp. 2487–2498, 2012. View at Publisher · View at Google Scholar · View at Scopus
  29. M. Linnebacher, C. Maletzki, C. Ostwald et al., “Cryopreservation of human colorectal carcinomas prior to xenografting,” BMC Cancer, vol. 10, article 362, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. C. Maletzki, S. Stier, U. Gruenert et al., “Establishment, characterization and chemosensitivity of three mismatch repair deficient cell lines from sporadic and inherited colorectal carcinomas,” PLoS ONE, vol. 7, no. 12, Article ID e52485, 2012. View at Publisher · View at Google Scholar · View at Scopus
  31. B. S. Danes, P. Deangelis, F. Traganos, M. R. Melamed, and T. Alm, “Demonstration of altered cellular DNA content distribution in long-term colon epithelial cell lines with colon cancer genotypes,” Scandinavian Journal of Gastroenterology, vol. 23, no. 7, pp. 840–846, 1988. View at Publisher · View at Google Scholar · View at Scopus
  32. J. Bocsi and A. Zalatnai, “Establishment and long-term xenografting of human pancreatic carcinomas in immunosuppressed mice: changes and stability in morphology, DNA ploidy and proliferation activity,” Journal of Cancer Research and Clinical Oncology, vol. 125, no. 1, pp. 9–19, 1999. View at Publisher · View at Google Scholar · View at Scopus
  33. S. Kang, A. G. Bader, and P. K. Vogt, “Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 3, pp. 802–807, 2005. View at Publisher · View at Google Scholar · View at Scopus
  34. F. Lange, K. Rateitschak, C. Kossow, O. Wolkenhauer, and R. Jaster, “Insights into erlotinib action in pancreatic cancer cells using a combined experimental and mathematical approach,” World Journal of Gastroenterology, vol. 18, no. 43, pp. 6226–6234, 2012. View at Publisher · View at Google Scholar · View at Scopus
  35. F. Lange, K. Rateitschak, B. Fitzner, R. Pöhland, O. Wolkenhauer, and R. Jaster, “Studies on mechanisms of interferon-gamma action in pancreatic cancer using a data-driven and model-based approach,” Molecular Cancer, vol. 10, article 13, 2011. View at Publisher · View at Google Scholar · View at Scopus
  36. H. Kamiyama, S. Rauenzahn, J. S. Shim et al., “Personalized chemotherapy profiling using cancer cell lines from selectable mice,” Clinical Cancer Research, vol. 19, no. 5, pp. 1139–1146, 2013. View at Publisher · View at Google Scholar · View at Scopus
  37. B. Vécsey-Semjén, K.-F. Becker, A. Sinski et al., “Novel colon cancer cell lines leading to better understanding of the diversity of respective primary cancers,” Oncogene, vol. 21, no. 30, pp. 4646–4662, 2002. View at Publisher · View at Google Scholar · View at Scopus
  38. E. Tulchinsky, “Fos family members: regulation, structure and role in oncogenic transformation,” Histology and Histopathology, vol. 15, no. 3, pp. 921–928, 2000. View at Google Scholar · View at Scopus
  39. K. T. Flaherty, J. R. Infante, A. Daud et al., “Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations,” The New England Journal of Medicine, vol. 367, no. 18, pp. 1694–1703, 2012. View at Publisher · View at Google Scholar · View at Scopus